[HTML][HTML] Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
Background The United States (US) Expanded Access Program (EAP) to coronavirus disease
2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of …
2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of …
[HTML][HTML] Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
…, N van Helmond, JW Senefeld, MM Petersen… - Nature …, 2021 - nature.com
Successful therapeutics and vaccines for coronavirus disease 2019 (COVID-19) have
harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
harnessed the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy …
…, DM Routman, WS Harmsen, MM Petersen… - Radiotherapy and …, 2020 - Elsevier
Background and purpose IMPT improves normal tissue sparing compared to VMAT in treating
oropharyngeal cancer (OPC). Our aim was to assess if this translates into clinical benefits. …
oropharyngeal cancer (OPC). Our aim was to assess if this translates into clinical benefits. …
Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer
…, TC Mullikin, WS Harmsen, MM Petersen… - Radiotherapy and …, 2020 - Elsevier
Purpose/objective(s) To report tumor genomic factors associated with overall survival (OS)
and local failure (LF) for patients with colorectal cancer (CRC) who received metastasis-…
and local failure (LF) for patients with colorectal cancer (CRC) who received metastasis-…
Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib
Y Ha, MA Mohamed Ali, MM Petersen… - Hepatology …, 2020 - Springer
Background The ability of the pretreatment lymphocyte to monocyte ratio (LMR) to predict
outcomes of patients with hepatocellular carcinoma (HCC) receiving sorafenib is not …
outcomes of patients with hepatocellular carcinoma (HCC) receiving sorafenib is not …
Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma
…, CC Wiggins, KA Bruno, MA Golafshar, MM Petersen… - medRxiv, 2021 - medrxiv.org
Background The United States (US) Expanded Access Program (EAP) to COVID-19
convalescent plasma was initiated in response to the rapid spread of severe acute respiratory …
convalescent plasma was initiated in response to the rapid spread of severe acute respiratory …
[HTML][HTML] Chemoradiotherapy for patients with locally advanced or unresectable extra-hepatic biliary cancer
…, TC Mullikin, WS Harmsen, MM Petersen… - Journal of …, 2020 - ncbi.nlm.nih.gov
Background Although surgical resection is the preferred curative-intent treatment option for
patients with non-metastatic, extra-hepatic biliary cancer (EBC), radiotherapy (RT) or …
patients with non-metastatic, extra-hepatic biliary cancer (EBC), radiotherapy (RT) or …
[HTML][HTML] Clinical outcomes for hilar and extrahepatic cholangiocarcinoma with adjuvant, definitive, or liver transplant-based neoadjuvant chemoradiotherapy strategies …
BS Laughlin, MM Petersen, YY Nathan… - Journal of …, 2022 - ncbi.nlm.nih.gov
Background We report our experience with 3 strategies for treating hilar and extrahepatic
cholangiocarcinoma (CCA) including chemoradiotherapy: neoadjuvant chemoradiotherapy (…
cholangiocarcinoma (CCA) including chemoradiotherapy: neoadjuvant chemoradiotherapy (…
Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn's disease: single-center series
…, F Grass, A Alsughayer, MM Petersen… - Crohn's & Colitis …, 2019 - academic.oup.com
Introduction The impact of ustekinumab on adverse postoperative outcomes in Crohn’s
disease (CD) remains largely unknown. We determined the difference in 90-day postoperative …
disease (CD) remains largely unknown. We determined the difference in 90-day postoperative …
Electrocardiogram-gated computed tomography with coronary angiography for cardiac substructure delineation and sparing in patients with mediastinal lymphomas …
SC Lester, K Taparra, MM Petersen, RK Funk… - Practical radiation …, 2020 - Elsevier
Purpose (1) Demonstrate feasibility of electrocardiogram-gated computed tomography with
coronary angiography (E-CTA) in treatment planning for mediastinal lymphoma and (2) …
coronary angiography (E-CTA) in treatment planning for mediastinal lymphoma and (2) …
